This page uses content from Wikipedia and is licensed under CC BY-SA.

Mitiglinide

Mitiglinide
Mitiglinide.svg
Clinical data
Trade namesGlufast
AHFS/Drugs.comInternational Drug Names
Routes of
administration
By mouth (tablets)
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H25NO3
Molar mass315.41 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Mitiglinide (INN,[1] trade name Glufast) is a drug for the treatment of type 2 diabetes.[2]

Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

Pharmacology

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive potassium KATP channels in pancreatic β cells.

Dosage

Mitiglinide is delivered in tablet form.

References

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names (Rec. INN): List 40" (PDF). World Health Organization. p. 187. Retrieved 10 November 2016.
  2. ^ Malaisse WJ (October 2008). "Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients". Expert Opin Pharmacother. 9 (15): 2691–8. doi:10.1517/14656566.9.15.2691. PMID 18803455. Archived from the original on 2015-09-24.

External links